Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases. (16th November 2016)

• Record Type: Journal Article
• Authors: Kobayashi, Ryu; Tamura, Kouichi; Wakui, Hiromichi; Ohsawa, Masato; Azushima, Kengo; Haku, Sona; Uneda, Kazushi; Ohki, Kohji; Haruhara, Kotaro; Kinguchi, Sho; Umemura, Satoshi
• Is Part Of: Clinical and experimental hypertension. Volume 38:Number 8(2016)
• Page Start: 744
• Page End: 750
• Publication Date: 2016-11-16
• Subjects: Albuminuria -- arterial stiffness -- blood pressure variability -- chronic kidney disease -- home blood pressure -- single-pill combination-based therapy; Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.1080/10641963.2016.1200063
• Languages: English
• ISSNs: 1064-1963

Abstract

ABSTRACT: We examined the efficacy of single-pill irbesartan/amlodipine combination-based therapy for 12 weeks in 20 hypertensive chronic kidney disease (CKD) patients, by evaluating self-measured home blood pressure (BP) profile. The single-pill irbesartan/amlodipine combination-based therapy decreased clinic BP and home BP (morning, evening, and nighttime BPs), and improved within-visit clinic BP variability, day-by-day home BP variability (morning and evening), and nighttime home BP variability. Furthermore, the single-pill combination-based therapy reduced albuminuria and exerted improved parameters of vascular function. These results indicate that this single-pill combination-based therapy may exert beneficial effects on clinic and home BP profiles as well as on renal and vascular damages, in hypertension with CKD.